information provided by the TGA on the safety, quality and efficacy of medicines and the safety, quality and performance of medical devices included on the Australian Register of Therapeutic Goods (ARTG) including: Australian Public Assessment Reports for prescription medicines; Approved Product Information; Consumer Medicine Information; Public summary documents on the ARTG; TGA Advisories and Medicines Safety Updates; and any problems that you have encountered in regard to the transparency of TGA processes and decision- making. If you participate in the production or marketing of therapeutic goods, please provide comment on: what ways you the TGA could provide greater assistance to you in the evaluation and registration, listing or marketing processes; and any issues that you have encountered in regard to the transparency of TGA processes and decision-making. If you work in the media, we would appreciate your comments on the timeliness, quality and utility of information provided in response to enquiries and/or Freedom of Information requests. You are invited to comment on any matters relevant to the of Reference. Please note that all submissions will be made available on the TGA website. To make a comment or a submission you can either email it to the Review Secretariat at OR mail it to: Transparency Review Secretariat Therapeutic Goods Administration WODEN ACT 2606 Submissions must reach the Secretariat no later than Friday 11 February 2011. The Panel will hold a limited number of public meetings in late February and March 2011 and details about these will be provided on the TGA website on Thursday 3 February 2011. I look forward to receiving your views. Yours sincerely
information provided by the TGA on the safety, quality and efficacy of medicines and the safety, quality and performance of medical devices included on the Australian Register of Therapeutic Goods (ARTG) including: Australian Public Assessment Reports for prescription medicines; Approved Product Information; Consumer Medicine Information; Public summary documents on the ARTG; TGA Advisories and Medicines Safety Updates; and any problems that you have encountered in regard to the transparency of TGA processes and decision- making. If you participate in the production or marketing of therapeutic goods, please provide comment on: what ways you the TGA could provide greater assistance to you in the evaluation and registration, listing or marketing processes; and any issues that you have encountered in regard to the transparency of TGA processes and decision-making. If you work in the media, we would appreciate your comments on the timeliness, quality and utility of information provided in response to enquiries and/or Freedom of Information requests. You are invited to comment on any matters relevant to the of Reference. Please note that all submissions will be made available on the TGA website. To make a comment or a submission you can either email it to the Review Secretariat at OR mail it to: Transparency Review Secretariat Therapeutic Goods Administration WODEN ACT 2606 Submissions must reach the Secretariat no later than Friday 11 February 2011. The Panel will hold a limited number of public meetings in late February and March 2011 and details about these will be provided on the TGA website on Thursday 3 February 2011. I look forward to receiving your views. Yours sincerely
review-tga-transparency-1101-final-report.docx